Top 5 Vaccines Manufacturers held 76% of the Global Vaccines Market

12 February 2019
Pharma

Visiongain has launched a new pharma report Vaccines Manufacturers Market Report : Merck & Co., Sanofi, Pfizer, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Emergent Biosolutions, Other Companies

The world vaccines market is set to grow steadily over the next 10 years. This growth is mainly driven by a global ageing population, as the elderly are more prone to contracting infections due to their pre-existing health conditions and a weak immune system. Demand from the emerging markets further drive growth as their middle class gets wealthier and demand better healthcare systems, furthermore the high birth rates in the emerging markets will feed the paediatric vaccines segment. Moreover, the vaccine industry benefits from strong research and development leading to continuous innovation. Technological advancements will be made in vaccine delivery and administration. As a result, the development of more efficient technology will reduce costs of vaccine production, making the entire manufacturing and supply chain more efficient.

The lead analyst of the report commented "Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development. New target sites, ways of generating an immune response and method of administration are already being investigated and, in some cases, successfully implemented. Further progress is expected to be made in this field as companies look for other ways to gain a competitive edge over their rivals, which could just be another way of administering an existing vaccine. This factor is expected to provide strong growth opportunities to vaccines manufacturers."

Leading companies featured in the report include Astellas Pharma Inc., AstraZeneca, Bavarian, Nordic, CSL Ltd., Emergent Biosolutions, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline PLC, Inovio Pharmaceuticals and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever